Forum
»
Klaus Schwab reportedly met with Pfizer CEO in Davos for 3+ hours
- Results 1 to 17 of 17
-
Page 1 of 1
01-18-2024, 06:50 AM
-
#1
- LizzieTish
- Registered User
-
- LizzieTish
- Registered User
- Join Date: Aug 2011
- Age: 51
- Posts: 8,412
- Rep Power: 55161
-
-
Klaus Schwab reportedly met with Pfizer CEO in Davos for 3+ hours
"The reason we are being murdered with genetic altering drugs is its slow acting and it causes your body to malfunction and destroy itself so there is a "plausible deniability" factor. Unlike most poisons which leave more evidence of being the direct cause of death."
1,151+ pages of peoples accounts of Covid-19 vaccine damage:
https://vestibular.org/forum/dizziness/covid-19-vaccine-side-effects/
01-18-2024, 07:08 AM
-
#2
01-18-2024, 07:08 AM
-
#3
- JayDigital
- Buy Hi HODL Sell Low Crew
-
- JayDigital
- Buy Hi HODL Sell Low Crew
- Join Date: May 2011
- Posts: 2,818
- Rep Power: 19398
-
-
brb ordering a year's supply of toilet paper
01-18-2024, 07:19 AM
-
#4
- ithappenss
- Registered User
-
- ithappenss
- Registered User
- Join Date: Jul 2020
- Age: 56
- Posts: 2,765
- Rep Power: 12553
-
-
just 2 weeks every election cycle
01-18-2024, 07:20 AM
-
#5
Round 2 of international Psy-Op in coming. Keep those feet moving and remember to bob and weave, gotta be like a young Tyson against these creeps.
**Florida Crew**
**Waiting for National Guard Bus Ride to Labor Camp Crew**
01-18-2024, 07:44 AM
-
#6
01-18-2024, 08:53 AM
-
#7
- TugOfPeace
- 1012 ng/dl
-
- TugOfPeace
- 1012 ng/dl
- Join Date: Oct 2013
- Posts: 4,986
- Rep Power: 166022
-
-
lol OP visits legitimate conspiracy theory forums
Monster0ultra self proclaimed "Chad" face pic looks like vtech school shooter: https://i.imgur.com/z2m6Why.jpg
01-18-2024, 08:56 AM
-
#8
01-18-2024, 08:58 AM
-
#9
- ithappenss
- Registered User
-
- ithappenss
- Registered User
- Join Date: Jul 2020
- Age: 56
- Posts: 2,765
- Rep Power: 12553
-
-
Originally Posted By TugOfPeace⏩
there's literaly no conspiracy about klaus or pfizer tho. evil german manlol OP visits legitimate conspiracy theory forums
01-18-2024, 09:04 AM
-
#10
- TugOfPeace
- 1012 ng/dl
-
- TugOfPeace
- 1012 ng/dl
- Join Date: Oct 2013
- Posts: 4,986
- Rep Power: 166022
-
-
Originally Posted By ithappenss⏩
If the WEF is this vocal about disease x and naturally occurring pandemics occur every 100-200 years, they'd have to be extremely bold and stupid to release such a disease now.there's literaly no conspiracy about klaus or pfizer tho. evil german man
Monster0ultra self proclaimed "Chad" face pic looks like vtech school shooter: https://i.imgur.com/z2m6Why.jpg
01-18-2024, 09:22 AM
-
#11
- CuttyUnderleaf
- Unregistered User
-
- CuttyUnderleaf
- Unregistered User
- Join Date: Feb 2020
- Posts: 6,205
- Rep Power: 182033
-
-
People believe anything on Twitter as long as it’s posted in all caps by a blue check mark
“All my pension I put into Pfizer stock,” - “I’m all in.”
Regulatory filings with the Securities and Exchange Commission show that Bourla acquired more than 375,000 units of Pfizer in mid-December at a price of $26.63—a $10 million move. The company confirmed the purchase was made with holdings from a pension fund of Bourla’s.
It’s a personal bet on Pfizer executing a turnaround—one that Bourla wants to oversee himself, as Wall Street raises questions over the future of his leadership.
That includes the pricey, $43 billion acquisition of biotech Seagen, which has a focus on cancer that could define Pfizer’s future. The company projects that it will reap $10 billion in annual revenue by 2030 from the acquisition, though analysts say Seagen’s four marketed products hold risks, including competition from other new drugs.
“One plus one equals three” in the case of Seagen and Pfizer together, Bourla says. “We should be able to do things that they wouldn’t be able to do before alone.”
Like acquisitions before it, Seagen will be key for Pfizer as the company braces itself to lose $17 billion in annual revenue between 2025 and 2030—on a revenue base of $52 billion next year, excluding Covid products—as a string of patents expire.
But the market hasn’t loved the deals. And attempts to bridge the gap from the patent cliff with in-house R&D—which analysts estimate topped $12 billion in 2023—have hit snags, including dumping two weight-loss pills that could have been a game-changing opportunity. “We will continue and I’m sure that successes will come,” Bourla says.
Speaking at the J.P. Morgan Healthcare Conference last week, Bourla outlined a focus on paying down debt and said there will be no more big acquisitions. Implying that stock buybacks are coming may be another attempt to placate Wall Street.
https://archive.is/gben6
“All my pension I put into Pfizer stock,” - “I’m all in.”
Regulatory filings with the Securities and Exchange Commission show that Bourla acquired more than 375,000 units of Pfizer in mid-December at a price of $26.63—a $10 million move. The company confirmed the purchase was made with holdings from a pension fund of Bourla’s.
It’s a personal bet on Pfizer executing a turnaround—one that Bourla wants to oversee himself, as Wall Street raises questions over the future of his leadership.
That includes the pricey, $43 billion acquisition of biotech Seagen, which has a focus on cancer that could define Pfizer’s future. The company projects that it will reap $10 billion in annual revenue by 2030 from the acquisition, though analysts say Seagen’s four marketed products hold risks, including competition from other new drugs.
“One plus one equals three” in the case of Seagen and Pfizer together, Bourla says. “We should be able to do things that they wouldn’t be able to do before alone.”
Like acquisitions before it, Seagen will be key for Pfizer as the company braces itself to lose $17 billion in annual revenue between 2025 and 2030—on a revenue base of $52 billion next year, excluding Covid products—as a string of patents expire.
But the market hasn’t loved the deals. And attempts to bridge the gap from the patent cliff with in-house R&D—which analysts estimate topped $12 billion in 2023—have hit snags, including dumping two weight-loss pills that could have been a game-changing opportunity. “We will continue and I’m sure that successes will come,” Bourla says.
Speaking at the J.P. Morgan Healthcare Conference last week, Bourla outlined a focus on paying down debt and said there will be no more big acquisitions. Implying that stock buybacks are coming may be another attempt to placate Wall Street.
https://archive.is/gben6
01-18-2024, 09:25 AM
-
#12
- TugOfPeace
- 1012 ng/dl
-
- TugOfPeace
- 1012 ng/dl
- Join Date: Oct 2013
- Posts: 4,986
- Rep Power: 166022
-
-
Originally Posted By CuttyUnderleaf⏩
With all the people who got jabbed, if there are any cancer side effects Pfizer will be the one to provide a cure through more vaccines. Doesn't surprise me..People believe anything on Twitter as long as it’s posted in all caps by a blue check mark
“All my pension I put into Pfizer stock,” - “I’m all in.”
Regulatory filings with the Securities and Exchange Commission show that Bourla acquired more than 375,000 units of Pfizer in mid-December at a price of $26.63—a $10 million move. The company confirmed the purchase was made with holdings from a pension fund of Bourla’s.
It’s a personal bet on Pfizer executing a turnaround—one that Bourla wants to oversee himself, as Wall Street raises questions over the future of his leadership.
That includes the pricey, $43 billion acquisition of biotech Seagen, which has a focus on cancer that could define Pfizer’s future. The company projects that it will reap $10 billion in annual revenue by 2030 from the acquisition, though analysts say Seagen’s four marketed products hold risks, including competition from other new drugs.
“One plus one equals three” in the case of Seagen and Pfizer together, Bourla says. “We should be able to do things that they wouldn’t be able to do before alone.”
Like acquisitions before it, Seagen will be key for Pfizer as the company braces itself to lose $17 billion in annual revenue between 2025 and 2030—on a revenue base of $52 billion next year, excluding Covid products—as a string of patents expire.
But the market hasn’t loved the deals. And attempts to bridge the gap from the patent cliff with in-house R&D—which analysts estimate topped $12 billion in 2023—have hit snags, including dumping two weight-loss pills that could have been a game-changing opportunity. “We will continue and I’m sure that successes will come,” Bourla says.
Speaking at the J.P. Morgan Healthcare Conference last week, Bourla outlined a focus on paying down debt and said there will be no more big acquisitions. Implying that stock buybacks are coming may be another attempt to placate Wall Street.
https://archive.is/gben6
“All my pension I put into Pfizer stock,” - “I’m all in.”
Regulatory filings with the Securities and Exchange Commission show that Bourla acquired more than 375,000 units of Pfizer in mid-December at a price of $26.63—a $10 million move. The company confirmed the purchase was made with holdings from a pension fund of Bourla’s.
It’s a personal bet on Pfizer executing a turnaround—one that Bourla wants to oversee himself, as Wall Street raises questions over the future of his leadership.
That includes the pricey, $43 billion acquisition of biotech Seagen, which has a focus on cancer that could define Pfizer’s future. The company projects that it will reap $10 billion in annual revenue by 2030 from the acquisition, though analysts say Seagen’s four marketed products hold risks, including competition from other new drugs.
“One plus one equals three” in the case of Seagen and Pfizer together, Bourla says. “We should be able to do things that they wouldn’t be able to do before alone.”
Like acquisitions before it, Seagen will be key for Pfizer as the company braces itself to lose $17 billion in annual revenue between 2025 and 2030—on a revenue base of $52 billion next year, excluding Covid products—as a string of patents expire.
But the market hasn’t loved the deals. And attempts to bridge the gap from the patent cliff with in-house R&D—which analysts estimate topped $12 billion in 2023—have hit snags, including dumping two weight-loss pills that could have been a game-changing opportunity. “We will continue and I’m sure that successes will come,” Bourla says.
Speaking at the J.P. Morgan Healthcare Conference last week, Bourla outlined a focus on paying down debt and said there will be no more big acquisitions. Implying that stock buybacks are coming may be another attempt to placate Wall Street.
https://archive.is/gben6
Monster0ultra self proclaimed "Chad" face pic looks like vtech school shooter: https://i.imgur.com/z2m6Why.jpg
01-18-2024, 09:30 AM
-
#13
- CuttyUnderleaf
- Unregistered User
-
- CuttyUnderleaf
- Unregistered User
- Join Date: Feb 2020
- Posts: 6,205
- Rep Power: 182033
-
-
Originally Posted By TugOfPeace⏩
Pfizer won’t provide the cure. They bought a company that does.With all the people who got jabbed, if there are any cancer side effects Pfizer will be the one to provide a cure through more vaccines. Doesn't surprise me..
https://archive.is/3AJ8D
01-18-2024, 09:49 AM
-
#14
- CuttyUnderleaf
- Unregistered User
-
- CuttyUnderleaf
- Unregistered User
- Join Date: Feb 2020
- Posts: 6,205
- Rep Power: 182033
-
-
Originally Posted By TugOfPeace⏩
Looks like Seagen doesn’t create vaccines, just treatments.With all the people who got jabbed, if there are any cancer side effects Pfizer will be the one to provide a cure through more vaccines. Doesn't surprise me..
I’ll have to research a bit more-inb4 my hyperfocus kicks in -_-
As a pioneer in antibody–drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics for more than 20 years. Our research team is highly motivated to build an innovative pipeline of transformative cancer therapeutics accelerated by best-in-class technology platforms. Our science is inspired by a singular mission—to make a real difference for people impacted by cancer.
Today, our research efforts are dedicated to advancing a pipeline of:
-Programs using our proprietary ADC technologies
-Novel antibodies and other targeted cancer therapeutics
-New classes of ADC linkers that incorporate novel small molecule payloads to kill tumor cells and induce an anti-tumor immune response
-Novel antibody engineering technologies
-ADCs in combination with checkpoint inhibitors
01-18-2024, 10:05 AM
-
#15
- DesiredUserphag
- 1:12TilTheDayIFukinDie
-
- DesiredUserphag
- 1:12TilTheDayIFukinDie
- Join Date: Sep 2014
- Posts: 40,176
- Rep Power: 397140
-
-
Gotta work out how they'll push the next BS on all the retards
𝗣𝗨𝗥𝗘𝗕𝗟𝗢𝗢𝗗
ωσяℓ∂ тяανєℓєя ȼяєω ₅₀/₁₉₅
𝕬𝖊𝖘𝖙𝖍𝖊𝖙𝖎𝖈𝖆𝖑𝖑𝖞 𝕮𝖚𝖙 𝕸𝖆𝖘𝖙𝖊𝖗 𝕽𝖆𝖈𝖊 ®
ᗪIᔕᑕᖇIᗰIᑎᗩTIOᑎ E᙭ᑕᒪᑌᔕIOᑎ IᑎᗪOᑕTᖇIᑎᗩTIOᑎ
01-18-2024, 10:26 AM
-
#16
- multiplemiggs
- P E R V E R T
-
- multiplemiggs
- P E R V E R T
- Join Date: Nov 2019
- Posts: 57,385
- Rep Power: 568972
-
-
Originally Posted By dmaaack⏩
ThisPandemic 2024 on the way
SPOT SOLD TO FROGTECH - 100% NATURAL GENETIC FROG FIBRES
see Krackerjacked's sig
never underestimate the slootiness of a sloot
-DrugsToGetBig
ratchet girls love the ebt flex
-havoc00
01-18-2024, 10:38 AM
-
#17
- Tyroneonahorse
- Registered User
-
- Tyroneonahorse
- Registered User
- Join Date: Dec 2019
- Age: 56
- Posts: 1,233
- Rep Power: 9423
-
-
Originally Posted By ithappenss⏩
He’s not German though, he’s one the Germans were trying to get rid ofthere's literaly no conspiracy about klaus or pfizer tho. evil german man
Bookmarks
-
- Digg
-
- del.icio.us
-
- StumbleUpon
-
-
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts